At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 24, 2026 at 08:00 ET
Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Cardiology Annual Meeting, showing cardiovascular and quality-of-life benefits in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, irrespective of BMI. The data suggest potential mechanistic benefits via reduction in epicardial fat, supporting broader application in cardiometabolic diseases. While not a regulatory approval, the findings reinforce the drug’s therapeutic potential in late-stage development.
- Sotagliflozin demonstrated reduced heart failure and MACE events across BMI strata in the SCORED trial.
- In the SOTA-P-CARDIA trial, sotagliflozin improved quality of life and physical function in non-diabetic HFpEF patients.
- Potential mechanistic benefit observed via reduction in epicardial adipose tissue.
- Data presented at ACC 2026, a major medical conference, adding clinical credibility.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access